For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

LAE002INT2001/GOG-3044

Trial Overview

Official Title

An Open-Label Randomized Active- Controlled Phase Ii Clinical Study To Assess The Efficacy And Safety Of Afuresertib Plus Paclitaxel Versus Paclitaxel In Patients With Platinum-Resistant Ovarian Cancer

Study Purpose

To evaluate the efficacy of afuresertib in combination with paclitaxel when compared to paclitaxel alone in patients with platinum-resistant ovarian cancer.

Diagnosis

Patients who have platinum-resistant ovarian cancer.

Eligibility

Platinum resistant ovarian cancer. Measurable disease.

1 to 3 prior chemotherapies

No more than 1 in the platinum resistant setting.

Must have prior use of bevacizumab (unless contraindicated).

Tumor tissue within 1 year or fresh biopsy.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

Patients will be assigned to one of the two treatment arms:

Group 1: Patients will receive combination treatment of afuresertib in combination with paclitaxel.

Group 2: Patients will receive treatment with only paclitaxel.

For more information, visit Clinicaltrials.gov

Key Participation Requirements
Gender
Female
Age
19 years and older
Enrollment Status
Available
Phase
Phase II
Methodist Health System Trial Code
LAE002INT2001/GOG-3044
Related Specialties